Cue Biopharma (CUE) Amortization of Deferred Charges (2022 - 2025)
Cue Biopharma (CUE) posted Amortization of Deferred Charges of $9000.0 for Q4 2025, little changed sequentially from $9000.0 in Q3 2025, and little changed YoY from $9000.0 in Q4 2024.
Cue Biopharma (CUE) Amortization of Deferred Charges (2022 - 2025) Analysis & Trends
Cue Biopharma has reported Amortization of Deferred Charges for 4 years, with the latest figure at $9000.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges changed 0.0% year-over-year to $9000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $37000.0, changed 0.0% from the prior year.
- Amortization of Deferred Charges steadied at $9000.0 in Q4 2025 per CUE's latest filing, from $9000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $10000.0 in Q4 2022 and troughed at $3000.0 in Q1 2022.
- A 4-year average of $8704.4 and a median of $9000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 200.0% in 2023, down 7.29% in 2023.
- Over 4 years, Amortization of Deferred Charges stood at $10000.0 in 2022, then decreased by 7.29% to $9271.0 in 2023, then dropped by 2.92% to $9000.0 in 2024, then changed by 0.0% to $9000.0 in 2025.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $9000.0, $9000.0, and $9000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 9,271.00 |
| Dec 31, 2023 | 9,271.00 |
| Sep 30, 2023 | 9,000.00 |
| Sep 30, 2023 | 9,000.00 |